Clinical trials
catalyst calendar across sponsors →Studies where BLTE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 11 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MAVERICK CAPITAL LTD, Holocene Advisors, LP, CITADEL ADVISORS LLC, Duquesne Family Office LLC, +6 more) · FINRA short interest 6.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 13 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt DiseaseNCT06388083To measure the annualized rate of change from baseline lesion size in aggregate area of atrophyRandomized · Triple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Tinlarebant, Placebo | STGD1, Stargardt Disease 1 | 60 | Feb 2028 | ≤ 558 d | 2026-03-12 |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion sizeRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Tinlarebant, Placebo | Geographic Atrophy | 429 | 2027-06-30 | in 314 d | 2026-01-07 |
| Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baselineRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Tinlarebant, Placebo | Stargardt Disease 1 | 104 | 2025-08-04actual | — | 2026-07-23 |
| Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy AdultsNCT04005807Area under the plasma concentration versus time curve from time 0 to the last timepoint with quantifiable concentration [AUC(0-t)]Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: BPN-14967, Placebo | Healthy Volunteers | 40 | 2019-12-20actual | — | 2021-06-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19